Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 3/20 | 0.47 |
| ▸ | OPRD1 | P41143 | 3/20 | 0.47 |
| ▸ | KDR | P35968 | 1/20 | 0.44 |
| ▸ | BACE1 | P56817 | 7/20 | 0.44 |
| ▸ | NPY4R | P50391 | 7/20 | 0.44 |
| ▸ | NPY1R | P25929 | 5/20 | 0.44 |
| ▸ | NPY2R | P49146 | 4/20 | 0.44 |
| ▸ | NPY5R | Q15761 | 4/20 | 0.44 |
| ▸ | BACE2 | Q9Y5Z0 | 2/20 | 0.44 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14655975 | 0.87 | KDR (0.41) | OPRM1OPRD1KDRBACE1NPY4R | |
| SCHEMBL14968851 | 0.84 | KDR (0.39) | OPRM1OPRD1KDRBACE1NPY4R | |
| SCHEMBL4264976 | 0.84 | OPRD1 (0.55) | OPRM1OPRD1BACE1BACE2OPRK1 | |
| SCHEMBL3366840 | 0.81 | CASP1 (0.51) | OPRD1KDRBACE1BACE2 | |
| SCHEMBL2157759 | 0.81 | OPRD1 (0.52) | OPRM1OPRD1BACE1BACE2OPRK1 | |
| SCHEMBL1575643 | 0.81 | NPY4R (0.43) | NPY4RNPY1RNPY2RNPY5R | |
| SCHEMBL4321426 | 0.78 | BACE1 (0.44) | BACE1BACE2 | |
| SCHEMBL73897 | 0.76 | NPY4R (0.60) | OPRM1OPRD1BACE1NPY4RNPY1R | |
| SCHEMBL2383875 | 0.75 | MEN1 (0.47) | OPRM1OPRD1KDROPRK1 | |
| SCHEMBL11038734 | 0.75 | F2RL1 (0.42) | KDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2013014186-A1 | METHOD FOR PURIFICATION OF IMMUNOPROTEASOMES | ARES TRADING S.A. (CH) | 2013-01-31 | — | — | WO | disclosed |
| EP-1372598-B1 | USE OF A PHAEODACTYLUM ALGAE EXTRACT TO PROMOTE THE PROTEASOME ACTIVITY OF SKIN CELLS | LVMH RECH (FR) | 2011-08-17 | — | — | EP | disclosed |
| US-7220417-B2 | Use of phaeodactylum algae extract as cosmetic agent promoting the proteasome activity of skin cells and cosmetic composition comprising same | LVMH RECHERCHE (FR) | 2007-05-22 | — | — | US | disclosed |
| US-20040136945-A1 | Use of phaeodactylum algae extract as cosmetic agent promoting the proteasome activity of skin cells and cosmetic composition comprising same | LYMH RECHERCHE (FR) | 2004-07-15 | — | — | US | disclosed |
| EP-1372598-A2 | USE OF A PHAEODACTYLUM ALGAE EXTRACT TO PROMOTE THE PROTEASOME ACTIVITY OF SKIN CELLS | LVMH RECHERCHE (FR) | 2004-01-02 | — | — | EP | disclosed |
| WO-2002080876-A2 | USE OF A PHAEODACTYLUM ALGAE EXTRACT TO PROMOTE THE PROTEASOME ACTIVITY OF SKIN CELLS | LVMH RECHERCHE (FR) | 2002-10-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040136945-A1 | Use of phaeodactylum algae extract as cosmetic agent promoting the proteasome activity of skin cells and cosmetic composition comprising same | PSMG3, PSME1, PSMB5 | OPRM1 4661/4885OPRD1 4231/4885KDR 4665/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.